Wednesday, June 7, 2023 6/7/2023

Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.

Award Number: R01AI142670
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

PROJECT SUMMARY/ABSTRACT Over one million infants born to women living with HIV are spared from vertical HIV acquisition. This public health success is attributable to scaling up of maternal antiretroviral treatment (ART), with current World Health Organization (WHO) policies recommending lifetime ART for persons living with HIV, including pregnant women. Yet, HIV-exposed uninfected (HEU) infants in resource-constrained settings experience 2- to 4-fold higher infectious cause morbidity and mortality compared with HIV-unexposed (HU) infants in the same settings. This is primarily due to diarrheal disease and respiratory illness, including tuberculosis (TB). HEU children also experience 20-fold increased incidence of latent TB infection (LTBI) compared with HIV- unexposed (HU) children. Several studies have described immune abnormalities among HEU children, which might explain a portion of HEU infant vulnerability. In both Botswana and South Africa, also settings with high TB and HIV prevalence, bacille Calmette-Guérin (BCG) immunization rates at birth exceed 98%. While some studies have shown that BCG vaccination protects against TB meningitis and disseminated TB in HU infants and may have heterologous effects that extend beyond TB protection, the reported alterations in HEU infant immunity may impact the efficacy of the BCG vaccine both in directly protecting against TB and in providing the non-specific immune protection. Leveraging two existing prospective observational maternal-child health studies underway in Botswana and South Africa, respectively, each of which is following both HEU and HU infants from birth and beyond infancy, we will use data and specimens from 900 infants (600 HEU infants) to evaluate BCG vaccine-induced specific and non-specific immune responses while using immunological studies to assess correlates of BCG vaccine protection. Specifically, we will 1) Define TB-related and TB- independent causes of morbidity and mortality in BCG vaccinated HEU and HU infants; 2) Define immune correlates of risk for tuberculosis infection in HEU infants using polychromatic flow cytometry to compare conventional and unconventional T-cell responses to BCG vaccination; 3) Explore the effect of HIV exposure on BCG-induced peripheral blood monocytes. We anticipate that study findings will inform TB vaccine development for HEU infants,and might identify further potential interventions to protect against infectious morbidity and mortality more frequently experienced by this vulnerable population of infants.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $845,032 )
2023	2023	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	5	2/2/2023	NON-COMPETING CONTINUATION	$845,032


Issue Date FY: 2022 ( Subtotal = $1,058,752 )
2022	2022	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	4	1/12/2022	NON-COMPETING CONTINUATION	$769,880
2022	2022	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	4	7/26/2022	NON-COMPETING CONTINUATION	$156,035
2022	2022	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	002	4	8/4/2022	SUPPLEMENT FOR EXPANSION	$132,837


Issue Date FY: 2021 ( Subtotal = $747,678 )
2021	2021	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	3	9/15/2021	NON-COMPETING CONTINUATION	$124,251
2021	2021	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	3	1/7/2021	NON-COMPETING CONTINUATION	$623,427


Issue Date FY: 2020 ( Subtotal = $636,736 )
2020	2020	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	2	1/30/2020	NON-COMPETING CONTINUATION	$636,736


Issue Date FY: 2019 ( Subtotal = $724,699 )
2019	2019	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	000	1	2/13/2019	NEW	$725,756
2019	2019	MASSACHUSETTS GENERAL HOSPITAL, THE	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Allergy and Infectious Diseases Research	001	1	2/28/2019	NEW	-$1,057


Grand Total All Awards = $4,012,897

Sum of Action Amount is $4,012,897;

Grand Total = $4,012,897

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Immune correlates of tuberculosis and non-tuberculosis infectious morbidity in Southern African HIV-exposed, uninfected infants.

Award Number: R01AI142670

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer